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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with selective upper and lower motor neuron degeneration (Brown and Al-Chalabi, 2017; Swinnen and Robberecht, 2014) . Although traditionally viewed as a motor neuron disease, non-neuronal supporting cells extensively contribute to motor neuron degeneration (Boillee et al., 2006; Ilieva et al., 2009) . Oligodendrocytes are such contributing non-neuronal cells, as they degenerate during disease and are replaced by newly formed oligodendrocytes (Kang et al., 2013; Philips et al., 2013) . However, in both ALS patients and mutant SOD1 mice, these newly formed oligodendrocytes are immature and dysfunctional, as they insufficiently generate myelin basic protein (MBP) and monocarboxylate transporter 1 (MCT-1) (Kang et al., 2013; Lee et al., 2012; Philips et al., 2013) . Consequently, motor neurons lose an important source of structural and trophic support. Therefore, strategies to improve differentiation of oligodendrocyte progenitor cells (OPCs) towards mature and functional oligodendrocytes could be of therapeutic interest in ALS (Philips and Rothstein, 2017) .
Considerable efforts were made to shed new light on a plethora of factors that regulate oligodendrocyte differentiation (Li et al., 2009) . Different studies showed that Id2 and Notch1 are permissive for OPC expansion and inhibit their differentiation into functionally mature oligodendrocytes (Wang et al., 2001; Zhang et al., 2009) , suggesting their potential involvement in the oligodendrocyte pathology documented in ALS mice (Kang et al., 2013; Philips et al., 2013) .
In this study, we investigated whether oligodendroglial-specific deletion of these two master regulators of oligodendrocyte differentiation, maturation and functioning could reduce oligodendrocyte pathology and improve disease outcome in ALS mice. 
Methods
Transgenic mouse models
mice were purchased from the Jackson Laboratory. ID2 Lox/Lox mice were described previously (Niola et al., 2012) . PDGFαR-CreER mice (Kang et al., 2010) were kindly donated by Dwight E. Bergles (Johns Hopkins School of Medicine, Baltimore). All mice were maintained on a C57Bl6J background and littermate controls were used for this study. Cre-mediated recombination was induced at P60 by administering tamoxifen as described before (Philips et al., 2013) . The use and maintenance of all the mice used in this study was approved by the ethical committee of the University of Leuven, Belgium.
Motor performance, disease onset and end-point determination
Motor performance and disease onset were assessed by the hanging grid test, as described before (Staats et al., 2016) . End-stage was determined as described before (Van Hoecke et al., 2012) .
Immunoblot analysis
Protein lysates (30 µg) were loaded on a 10% (for MCT-1) or 15% (for MBP) SDS-polyacrylamide (SDS-PAGE) gel and processed as described before (Philips et al., 2013) . Following primary antibodies were used: anti-MBP (goat, 1/10,000; Santa Cruz, RRID: AB_648794), anti-MCT-1 (chicken, 1/1000; Millipore, RRID: AB_90565) and anti-GAPDH (Mouse, 1/2,000; Ambion, RRID: AB_437392).
Results
Disease outcome is not improved in ALS mice upon oligodendroglial deletion of Id2 or Notch1
To evaluate if oligodendroglial-specific deletion of Id2 or Notch1 could reduce oligodendrocyte pathology and improve disease outcome in ALS mice, we crossbred Id2 
Oligodendroglial deletion of Id2 or Notch1 does not improve oligodendrocyte dysfunction in ALS mice
MCT-1 and MBP are generally known as markers to assess terminally differentiated and functional oligodendrocytes in ALS (Kang et al., 2013; Philips et al., 2013) . We evaluated the expression of both proteins in the lumbar spinal cord of end-stage SOD1 G93A mice in which Id2 or Notch1 were selectively removed from the oligodendroglial cells, and compared it to control SOD1 G93A mice and age-matched SOD1 WT mice. We found that deleting Id2 or Notch1 is insufficient to correct MBP and MCT-1 levels OPCs is not sufficient to correct differentiation and functioning of the oligodendrocytes, at least in this ALS mouse model.
Discussion
Strong evidence suggests that degeneration of oligodendrocytes and improper replacement of the lost cells by newly formed immature and dysfunctional oligodendrocytes substantially contribute to the degeneration of the motor neurons (Kang et al., 2013; Philips et al., 2013) . We evaluated the potential of Id2 and Notch1, two master modulators of oligodendrocyte differentiation, maturation and functioning (Wang et al., 1998; Zhang et al., 2009) Notch1, such as Wnt-signaling, Nogo-A, Id4 and human endogenous retroviruses (HERVs), can be of particular importance to overcome the oligodendroglial pathology seen in ALS (Nonneman et al., 2014) .
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